Lenalidomida Aurovitas

Lenalidomide, the active ingredient in Lenalidomida Aurovitas, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, in adult patients who have relapsed or refractory disease.

GNH USA supplies Lenalidomida Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide, including hospitals, pharmacies and procurement teams, ensuring consistent quality and regulatory compliance across markets. The product adheres to EU pharmacopeial standards and is shipped with appropriate documentation.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone marrow. - Multiple myeloma: improves progression‑free survival and disease control in relapsed or refractory patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves blood counts. - Mantle cell lymphoma (relapsed): contributes to response rates when combined with other agents.

Lenalidomide is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Diarrhea - Nausea - Rash

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia or infection - Severe thrombocytopenia with bleeding - Secondary primary malignancies - Hepatic toxicity (elevated transaminases) - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing lenalidomide, clinicians should observe several precautionary measures to minimize risk. - Monitor blood counts regularly: watch for neutropenia and thrombocytopenia. - Assess renal function before initiation: dose adjustment may be required. - Evaluate thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid use in pregnancy: teratogenic potential requires strict contraception. - Review concomitant medications: potential for drug‑drug interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide may interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce lenalidomide effectiveness. - Anticoagulants (warfarin): heightened risk of bleeding. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase bleeding risk when combined with thrombocytopenia. - Other myelosuppressive agents (e.g., chemotherapy): additive bone‑marrow suppression. - CYP3A4 substrate drugs (e.g., statins): monitor for altered plasma levels. - Hormonal contraceptives: reduced efficacy, consider alternative methods.